Recombinant allergens: The present and the future

 Abstract

Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
1534 - 1543
doi
10.4161/hv.22064
Type
Special Focus Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Recombinant allergens: The present and the future